Gynecological cancer | Discussion・Q&A

解説【1064O】ICON8B: GCIG Phase III Randomised Trial Comparing First-line Weekly Dose-Dense Chemotherapy + Bevacizumab To Three-Weekly Chemotherapy + Bevacizumab In High-Risk Stage III-IV Epithelial Ovarian Cancer (EOC): Final Overall Survival (OS) Analysis

山本 香澄
（兵庫県立がんセンター）

解説【LBA3】Pembrolizumab vs Placebo Plus Weekly Paclitaxel ± Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer: Results from the Randomized Double-Blind Phase 3 ENGOT-ov65/KEYNOTE-B96 Study

山本 香澄
（兵庫県立がんセンター）

解説【LBA44】Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025

山本 香澄
（兵庫県立がんセンター）